How Do You Take Peptides?
Quick answer
How a peptide is taken is decided by its pharmacology, not by preference. Most peptides are destroyed in the gut and poorly absorbed, so approved products are usually injected; a few are engineered or formulated for oral or nasal use. Research-grade peptides are laboratory reagents, so the only legitimate route question is how to handle them in an experiment, not how to administer them to a person.
Key facts at a glance
| Dominant route | Subcutaneous or intravenous for most approved peptide medicines |
|---|---|
| Oral barrier | Gastric acid, proteases and poor epithelial permeability |
| Notable exception | Oral semaglutide, formulated with an absorption enhancer |
| Topical use | Cosmetic peptides, with deliberately limited skin penetration |
| Frequency driver | Half-life and mechanism, not convenience |
| Research-grade status | Not for human administration under any route |
Route is a pharmacology decision
A peptide has to reach its target in an intact, active form. Every route is a different obstacle course. Swallowed material meets acid and proteases before it meets the bloodstream. Material placed under the skin must be absorbed through connective tissue and survives protease activity there. Material applied to skin must cross the stratum corneum, which is designed to keep large molecules out.
Route therefore determines bioavailability, the shape of the plasma concentration curve and the exposure of non-target tissues. It also determines which impurities reach the body. For approved medicines, the route is fixed by the product licence because it was studied that way. Changing route changes the drug.
Bioavailability, the fraction of an administered amount that reaches circulation unchanged, is the usual measure. It explains why a route that works for one peptide fails for another of similar size: the difference lies in charge, stability and the enzymes at that particular surface.
How the main routes compare
| Route | Main barrier | Typical outcome |
|---|---|---|
| Oral | Acid, pepsin, pancreatic proteases, tight junctions | Very low bioavailability for most unmodified peptides |
| Sublingual or buccal | Salivary proteases, mucosal permeability | Variable and generally low; useful only for small, stable sequences |
| Intranasal | Mucociliary clearance, local proteases | Rapid absorption for a few approved products; inconsistent otherwise |
| Subcutaneous | Local proteases, absorption surface area | Slow, sustained exposure; standard for many peptide medicines |
| Intravenous | None, but systemic exposure is immediate | Complete bioavailability with the least margin for error |
| Topical | Stratum corneum | Minimal systemic exposure; effects largely local |
None of these rows is a recommendation. They describe why a route is chosen and what limits it.
Why most peptides cannot simply be swallowed
The gut is built to break peptides into amino acids. Pepsin works in the stomach, trypsin and chymotrypsin in the small intestine, and brush-border peptidases finish the job at the epithelial surface. A linear peptide of ten to thirty residues typically has a half-life in the intestinal lumen measured in minutes.
Formulation can partially compensate. Enteric coatings delay release, protease inhibitors slow degradation, and absorption enhancers loosen tight junctions. Each of those strategies has limits, and only a small number of products have solved them well enough for clinical use. Oral semaglutide required a specific enhancer and a strict administration procedure; it is the exception that demonstrates how difficult the problem is.
Why frequency cannot be generalised
The interval between administrations is set by how long the active molecule persists and how long its downstream effect lasts. A peptide with a half-life of minutes cannot be dosed weekly without modification; one that binds albumin or carries a fatty acid chain can persist for days. Some effects depend on continuous receptor occupancy, others on a transient pulse that triggers a lasting change.
This is why there is no general answer to how often peptides are taken. Approved products state an interval derived from pharmacokinetic and clinical data. Research peptides have no such dataset, and any schedule circulating online is an assertion rather than a finding.
What "how to take" means for research-grade material
For a laboratory reagent, the relevant procedures are dissolution, dilution, aliquoting and storage. The solvent matters: some sequences dissolve readily in water, others need a small amount of acetonitrile, dimethyl sulfoxide or a buffer at a defined pH. Dissolving the wrong way can cause aggregation that no later step reverses.
Those steps are analytical and experimental, not clinical. A research vial has not been manufactured to sterile standards, is not endotoxin-tested and carries no dose. MOL Changes supplies such material only for laboratory and manufacturing use, and the reconstitution guide describes the chemistry involved, not a method of administration.
Where route and quantity information goes wrong
Three errors recur in informal sources. The first is unit confusion: milligrams and micrograms differ by a factor of a thousand, and international units apply only to specific biological standards. The second is concentration arithmetic: adding a volume of diluent to a powder gives a concentration that depends on peptide content, not on the labelled mass alone. The third is assuming that a dose studied in one species or one formulation transfers to another.
A fourth error is treating a vendor protocol as evidence. Suppliers are not regulators, and a suggested schedule on a product page is marketing copy, not a clinical finding.
Questions to settle before an experiment
- Stability: how long does the peptide survive at the temperature, pH and concentration the assay requires?
- Solubility: what solvent gives a clear solution without aggregation, and does that solvent interfere with the readout?
- Adsorption: does the peptide stick to plastic or filter membranes at low concentration?
- Controls: is there a scrambled or inactive analogue, and a vehicle control, to separate the sequence effect from handling effects?
- Identity: does the batch certificate match the sequence actually being studied?
Answering these questions is what distinguishes a reproducible experiment from an anecdote, and it is also the basis for comparing results across published work. For related context, see whether peptides work and peptide solubility.
Frequently asked questions
How do you take peptides?
In medicine, the route is fixed by the approved product: most peptide medicines are injected, a few are formulated for oral or nasal use. In research, peptides are dissolved and handled as reagents. There is no universal route, and research-grade material is not intended for human use by any route.
Can you take peptides orally?
Only a minority. Most peptides are degraded by stomach acid and intestinal enzymes and cross the gut wall poorly, so oral bioavailability is very low. A few products overcome this with modifications or absorption enhancers. Oral peptide supplements are a separate category and generally provide nutrients rather than drug-like exposure.
How often do you take peptides?
It depends on the molecule. Half-life, receptor kinetics and the duration of the downstream effect determine the interval, and approved products set it from clinical data. No general schedule exists, and any frequency claimed for an unapproved peptide is not supported by the evidence base.
Do peptides have to be injected?
Most approved peptide medicines are injected because oral absorption is too low to be reliable. Topical cosmetic peptides are formulated for local skin effects, and a few products use nasal or oral routes. Injection is a consequence of molecular properties, not a mark of quality.
Can peptides be absorbed through the skin?
Intact peptides larger than a few hundred daltons penetrate the stratum corneum poorly. Cosmetic formulations sometimes use carriers or penetration enhancers, and some peptides act on the skin surface or in the upper epidermis. Claimed systemic effects from topical peptides are not well supported.
Sources and scope
This answer is based on peer-reviewed peptide chemistry and analytical literature, pharmacopoeial requirements (USP <503>, Ph. Eur. 2.2.29 and 2.2.46), FDA and EMA guidance on peptide drug substances, and MOL Changes in-house synthesis and testing data. Product statements describe research-grade peptides supplied for laboratory and manufacturing use. They are not medical advice and are not a substitute for clinical judgement.